References

1. Hamouda Boussen,Hatem Bouzaiene,Jamel Ben Hassouna,Tarek Dhiab,Fathi Khomsi,Farouk Benna,Amor Gamoudi,Nejib Mourali,Monia Hechiche,Khaled Rahal,Paul Levine (2010). Inflammatory breast cancer in Tunisia.
2. N Mourali,L Muenz,F Tabbane,S Belhassen,J Bahi (1980). Epidemiologic features of rapidly progressing breast cancer in Tunisia.
3. Shine Chang,Sheryl Parker,Tuan Pham,Aman Buzdar,Stephen Hursting (1998). Inflammatory breast carcinoma incidence and survival.
4. K Hance,W Anderson,S Devesa,H Young,P Levine (2005). Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.
5. James Lawson,Wendy Glenn,Brian Salmons,Yulan Ye,Benjamin Heng,Patrick Moody,Harpreet Johal,William Rawlinson,Warick Delprado,Louise Lutze-Mann,Noel Whitaker (2010). Mouse Mammary Tumor Virus–like Sequences in Human Breast Cancer.
6. S Singletary,Massimo Cristofanilli (2008). Defining the Clinical Diagnosis of Inflammatory Breast Cancer.
7. William Anderson,Catherine Schairer,Bingshu Chen,Kenneth Hance,Paul Levine (2005). Epidemiology of inflammatory breast cancer.
8. S Dawood,S Merajver,P Viens,P Vermeulen,S Swain,T Buchholz,L Dirix,P Levine,A Lucci,S Krishnamurthy,F Robertson,W Woodward,W Yang,N Ueno,M Cristofanilli (2011). International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.
9. Angelo Paradiso,Stefania Tommasi,Mario Brandi,Francesco Marzullo,Gianni Simone,Vito Lorusso,Anita Mangia,Mario De Lena (1989). Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease.
10. W Anderson,K Chu,S Chang (2003). Inflammatory breast carcinoma and non-inflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?.
11. A Benhammida,I Labidi,K Mrad,E Charafe-Jauffret,S Arab (2008). Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry.
12. N Chaher,H Arias-Pulido,N Terki,C Qualls,K Bouzid,C Verschraegen (2012). Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients Breast.
13. M Guerin,M Gabillot,Mc Mathieu,M Travagli,N Spielmann,Andrieu (1989). Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance.
14. Ana Gonzalez-Angulo,Nour Sneige,Aman Buzdar,Vicente Valero,Shu-Wan Kau,Kristine Broglio,Yuko Yamamura,Gabriel Hortobagyi,Massimo Cristofanilli (2004). p53 Expression as a Prognostic Marker in Inflammatory Breast Cancer.
15. C Kleer,K Van Golen,T Braun,S Merajver (2001). Persistent E-Cadherin Expression in Inflammatory Breast.
16. C Colpaert,P Vermeulen,I Benoy,A Soubry,F Van Roy,P Van Beest,G Goovaerts,L Dirix,P Van Dam,S Fox,A Harris,E Van Marck (2003). Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression.
17. L Kenneth,Seena Van Golen,Davies,Fen Zhi,Yunfang Wu,Corazon Wang,Bucana (1999). Holly Root, : A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory Breast cancer), and Rhoc GTPase correlate with the inflammatory breast cancer phenotype.
18. H Yamauchi,W Woodward,V Valero,R Alvarez,A Lucci,T Buchholz (2012). Inflammatory Breast Cancer: What We Know and What We Need to Learn.
19. T Naoto,Aman Ueno,Sonja Buzdar,Frederick Singletary,Marsha Ames,Mcneese (1997). Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center.
20. Massimo Cristofanilli,Ana Gonzalez-Angulo,Aman Buzdar,Shu-Wan Kau,Debbie Frye,Gabriel Hortobagyi (2004). Paclitaxel Improves the Prognosis in Estrogen Receptor—Negative Inflammatory Breast Cancer: The M. D. Anderson Cancer Center Experience.
21. Luca Gianni,Wolfgang Eiermann,Vladimir Semiglazov,Alexey Manikhas,Ana Lluch,Sergey Tjulandin,Milvia Zambetti,Federico Vazquez,Mikhail Byakhow,Mikhail Lichinitser,Miguel Climent,Eva Ciruelos,Belén Ojeda,Mauro Mansutti,Alla Bozhok,Roberta Baronio,Andrea Feyereislova,Claire Barton,Pinuccia Valagussa,Jose Baselga (2010). Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
22. B Chevallier,B Asselain,A Kunlin,C Veyret,P Bastit,Y Graic (1987). Inflammatory Breast Cancer Determination of Prognostic Factors by Univariate and Multivariate Analysis.
23. I Faneyte,J Schrama,J Peterse,P Remijnse,S Rodenhuis,M Van De Vijver (2003). Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome.
24. E Bélembaogo,V Feillel,P Chollet,H Curé,P Verrelle,F Kwiatkowski,J Achard,G Le Bouëdec,J Chassagne,Y Bignon (1992). Neoadjuvant chemotherapy in 126 operable breast cancers☆.
25. H Kuerer,L Newman,T Smith,F Ames,K Hunt,K Dhingra (1999). Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicinebased neoadjuvant chemotherapy.
26. Fredika Robertson,Melissa Bondy,Wei Yang,Hideko Yamauchi,Shannon Wiggins,Samira Kamrudin,Savitri Krishnamurthy,Huong Le-Petross,Luc Bidaut,Audrey Player,Sanford Barsky,Wendy Woodward,Thomas Buchholz,Anthony Lucci,Naoto Ueno,Massimo Cristofanilli (2010). Inflammatory Breast Cancer: The Disease, the Biology, the Treatment.
27. Cg,P Vermeulen,L Dirix,Van Marck,E (2003). Microvessel density, expression of oestrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast Cancer.
28. J Pierga,T Petit,T Delozier,J Ferrero,M Campone,J Gligorov (2012). Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.
29. S Rabiya,Tuma (2012). ALK gene amplified in most inflammatory breast cancers.